CA2697024C - Bilayers - Google Patents
Bilayers Download PDFInfo
- Publication number
- CA2697024C CA2697024C CA2697024A CA2697024A CA2697024C CA 2697024 C CA2697024 C CA 2697024C CA 2697024 A CA2697024 A CA 2697024A CA 2697024 A CA2697024 A CA 2697024A CA 2697024 C CA2697024 C CA 2697024C
- Authority
- CA
- Canada
- Prior art keywords
- bilayer
- hydrated
- lipid
- support
- hydrated support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000000499 gel Substances 0.000 claims description 92
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 102000004169 proteins and genes Human genes 0.000 claims description 86
- 239000000232 Lipid Bilayer Substances 0.000 claims description 62
- 108010052285 Membrane Proteins Proteins 0.000 claims description 53
- 239000003921 oil Substances 0.000 claims description 53
- 150000002632 lipids Chemical class 0.000 claims description 46
- 102000018697 Membrane Proteins Human genes 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000002356 single layer Substances 0.000 claims description 40
- 230000002209 hydrophobic effect Effects 0.000 claims description 31
- 239000000017 hydrogel Substances 0.000 claims description 27
- 239000011148 porous material Substances 0.000 claims description 21
- 229920000936 Agarose Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 16
- 230000037431 insertion Effects 0.000 claims description 16
- 108090000862 Ion Channels Proteins 0.000 claims description 15
- 102000004310 Ion Channels Human genes 0.000 claims description 15
- 230000003993 interaction Effects 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 15
- UKDDQGWMHWQMBI-UHFFFAOYSA-O 1,2-diphytanoyl-sn-glycero-3-phosphocholine Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C UKDDQGWMHWQMBI-UHFFFAOYSA-O 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 229920002401 polyacrylamide Polymers 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000012491 analyte Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000005945 translocation Effects 0.000 claims description 10
- 239000013554 lipid monolayer Substances 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 4
- FHQVHHIBKUMWTI-ZCXUNETKSA-N 1-palmitoyl-2-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-ZCXUNETKSA-N 0.000 claims description 4
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- -1 sterol lipids Chemical class 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 108090000301 Membrane transport proteins Proteins 0.000 claims description 2
- 102000003939 Membrane transport proteins Human genes 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229930182558 Sterol Natural products 0.000 claims description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 150000002190 fatty acyls Chemical class 0.000 claims description 2
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 2
- 150000002313 glycerolipids Chemical class 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- 229940074096 monoolein Drugs 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229940079938 nitrocellulose Drugs 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229930001119 polyketide Natural products 0.000 claims description 2
- 125000000830 polyketide group Chemical group 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 150000003313 saccharo lipids Chemical class 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 150000003135 prenol lipids Chemical class 0.000 claims 1
- 108091006146 Channels Proteins 0.000 description 38
- 229920000858 Cyclodextrin Polymers 0.000 description 25
- 239000002609 medium Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 13
- 239000003228 hemolysin Substances 0.000 description 13
- 101710092462 Alpha-hemolysin Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102000034573 Channels Human genes 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 102000035160 transmembrane proteins Human genes 0.000 description 5
- 108091005703 transmembrane proteins Proteins 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 230000009172 bursting Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003861 general physiology Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 238000000492 total internal reflection fluorescence microscopy Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010082845 Bacteriorhodopsins Proteins 0.000 description 1
- 208000031976 Channelopathies Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 238000001074 Langmuir--Blodgett assembly Methods 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101000606032 Pomacea maculata Perivitellin-2 31 kDa subunit Proteins 0.000 description 1
- 101000606027 Pomacea maculata Perivitellin-2 67 kDa subunit Proteins 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002379 porinlike Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/5432—Liposomes or microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0716264.7A GB0716264D0 (en) | 2007-08-21 | 2007-08-21 | Bilayers |
| GB0716264.7 | 2007-08-21 | ||
| PCT/GB2008/002805 WO2009024775A1 (en) | 2007-08-21 | 2008-08-19 | Bilayers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2697024A1 CA2697024A1 (en) | 2009-02-26 |
| CA2697024C true CA2697024C (en) | 2016-10-18 |
Family
ID=38566709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2697024A Active CA2697024C (en) | 2007-08-21 | 2008-08-19 | Bilayers |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20110041978A1 (enExample) |
| EP (1) | EP2183594B1 (enExample) |
| JP (1) | JP5797405B2 (enExample) |
| CN (1) | CN101821626B (enExample) |
| CA (1) | CA2697024C (enExample) |
| GB (1) | GB0716264D0 (enExample) |
| WO (1) | WO2009024775A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
| US20100196203A1 (en) | 2007-02-20 | 2010-08-05 | Gurdial Singh Sanghera | Formation of Lipid Bilayers |
| GB0724736D0 (en) | 2007-12-19 | 2008-01-30 | Oxford Nanolabs Ltd | Formation of layers of amphiphilic molecules |
| GB0913823D0 (en) * | 2009-08-07 | 2009-09-16 | Isis Innovation | Bilayers |
| US8313956B2 (en) * | 2010-03-09 | 2012-11-20 | Nokia Corporation | Apparatus and associated methods |
| EP3620185A1 (en) | 2010-10-06 | 2020-03-11 | President and Fellows of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
| EP2673638B1 (en) | 2011-02-11 | 2019-10-30 | Oxford Nanopore Technologies Limited | Mutant pores |
| WO2012142174A1 (en) | 2011-04-12 | 2012-10-18 | Electronic Biosciences Inc. | Site specific chemically modified nanopore devices |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| GB201119032D0 (en) | 2011-11-03 | 2011-12-14 | Isis Innovation | Multisomes: encapsulated droplet networks |
| GB201202519D0 (en) | 2012-02-13 | 2012-03-28 | Oxford Nanopore Tech Ltd | Apparatus for supporting an array of layers of amphiphilic molecules and method of forming an array of layers of amphiphilic molecules |
| JP6271505B2 (ja) | 2012-04-10 | 2018-01-31 | オックスフォード ナノポール テクノロジーズ リミテッド | 変異体ライセニンポア |
| PT2838515T (pt) | 2012-04-16 | 2020-02-25 | Harvard College | Composições de sílica mesoporosa para modular respostas imunológicas |
| US20150204873A1 (en) * | 2012-06-18 | 2015-07-23 | Electonic Biosciences, Inc. | Cell-free assay device and methods of use |
| GB201219201D0 (en) | 2012-10-25 | 2012-12-12 | Isis Innovation | Hydrogel network |
| GB201219196D0 (en) | 2012-10-25 | 2012-12-12 | Isis Innovation | Droplet assembly method |
| CA2889664C (en) | 2012-10-26 | 2020-12-29 | Oxford Nanopore Technologies Limited | Droplet interfaces |
| GB201313121D0 (en) | 2013-07-23 | 2013-09-04 | Oxford Nanopore Tech Ltd | Array of volumes of polar medium |
| KR102449271B1 (ko) * | 2012-12-07 | 2022-09-29 | 옥스포드 유니버시티 이노베이션 리미티드 | 3d 프린팅에 의한 비말 어셈블리 |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| CN103435269A (zh) * | 2013-08-21 | 2013-12-11 | 哈尔滨工业大学 | 一种固体支撑仿生膜体系的制备方法 |
| CA2937411C (en) | 2014-01-22 | 2023-09-26 | Oxford Nanopore Technologies Limited | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide |
| EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| EP3137627B1 (en) | 2014-05-02 | 2025-07-30 | Oxford Nanopore Technologies plc | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
| EP3169800B1 (en) | 2014-07-14 | 2020-11-18 | Oxford University Innovation Limited | Measurement of analytes with membrane channel molecules, and bilayer arrays |
| KR20170042794A (ko) | 2014-09-01 | 2017-04-19 | 브이아이비 브이지더블유 | 돌연변이체 csgg 포어 |
| WO2016055778A1 (en) | 2014-10-07 | 2016-04-14 | Oxford Nanopore Technologies Limited | Mutant pores |
| GB201418512D0 (en) | 2014-10-17 | 2014-12-03 | Oxford Nanopore Tech Ltd | Electrical device with detachable components |
| HK1247861A1 (zh) | 2015-01-30 | 2018-10-05 | President And Fellows Of Harvard College | 用於癌症治疗的肿瘤周围和肿瘤内部材料 |
| GB201502809D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Mutant pore |
| GB201502810D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Method |
| CN114099793A (zh) | 2015-04-10 | 2022-03-01 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
| WO2016166232A1 (en) | 2015-04-14 | 2016-10-20 | Katholieke Universiteit Leuven | Nanopores with internal protein adaptors |
| EP3317669B1 (en) | 2015-07-02 | 2024-03-13 | The University of Massachusetts | Membrane and droplet-interface bilayer systems and methods |
| US10481120B1 (en) | 2015-08-06 | 2019-11-19 | University Of Tennessee Research Foundation | Droplet based measurement of specific capacitance and interfacial tensions |
| AU2016369071B2 (en) | 2015-12-08 | 2022-05-19 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Modified nanopores, compositions comprising the same, and uses thereof |
| CN115487351A (zh) | 2016-02-06 | 2022-12-20 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
| US10371610B2 (en) | 2016-02-23 | 2019-08-06 | Noul Co., Ltd. | Contact-type patch, staining method using the same, and manufacturing method thereof |
| KR102478639B1 (ko) | 2016-02-23 | 2022-12-19 | 노을 주식회사 | 표지 물질을 저장하는 패치, 이를 이용하는 조직 진단 방법 및 장치 |
| KR20170099738A (ko) | 2016-02-23 | 2017-09-01 | 노을 주식회사 | 접촉식 염색 패치 및 그 제조 방법 |
| AU2017225374B2 (en) | 2016-03-02 | 2020-03-05 | Oxford Nanopore Technologies Limited | Mutant pore |
| US10465240B2 (en) | 2016-03-30 | 2019-11-05 | Roche Sequencing Solutions, Inc. | Electrical enhancement of bilayer formation |
| US10155979B2 (en) | 2016-03-30 | 2018-12-18 | Roche Molecular Systems, Inc. | Non-destructive bilayer monitoring using measurement of bilayer response to electrical stimulus |
| US10233486B2 (en) | 2016-03-30 | 2019-03-19 | Roche Sequencing Solutions, Inc. | Method for inline bilayer capacitance monitoring |
| EP4122949B1 (en) | 2016-04-06 | 2024-06-05 | Oxford Nanopore Technologies plc | Mutant pore |
| GB201611770D0 (en) | 2016-07-06 | 2016-08-17 | Oxford Nanopore Tech | Microfluidic device |
| EP3484448B1 (en) | 2016-07-13 | 2025-04-09 | President and Fellows of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| RU2770060C2 (ru) | 2016-08-02 | 2022-04-14 | Президент Энд Феллоуз Оф Гарвард Колледж | Биологические материалы для модуляции иммунных ответов |
| GB201615741D0 (en) | 2016-09-15 | 2016-11-02 | Univ College Cardiff Consultants Ltd | Artificial cells |
| FR3061440B1 (fr) * | 2017-01-05 | 2021-02-12 | Centre Nat Rech Scient | Procede de fabrication d’une membrane multicouche sur support solide a base de copolymere a blocs amphiphile |
| CN108329471A (zh) * | 2017-01-19 | 2018-07-27 | 天津大学 | 一种锂硫电池正极活性材料异戊烯醇-硫共聚物及制备方法 |
| GB201707122D0 (en) | 2017-05-04 | 2017-06-21 | Oxford Nanopore Tech Ltd | Pore |
| CN117106037B (zh) | 2017-06-30 | 2025-07-25 | 弗拉芒区生物技术研究所 | 新颖蛋白孔 |
| JP7058858B2 (ja) * | 2017-10-19 | 2022-04-25 | 地方独立行政法人神奈川県立産業技術総合研究所 | 脂質二重膜形成器具及びそれを用いた脂質二重膜形成方法 |
| DE102017126732A1 (de) * | 2017-11-14 | 2019-05-16 | Endress+Hauser Conducta Gmbh+Co. Kg | Sensormembran, Sensor, ein Messgerät umfassend den Sensor und Verwendung des Sensors |
| GB2568895B (en) | 2017-11-29 | 2021-10-27 | Oxford Nanopore Tech Ltd | Microfluidic device |
| GB2569630B (en) | 2017-12-21 | 2022-10-12 | Sharp Life Science Eu Ltd | Droplet Interfaces in Electro-wetting Devices |
| GB2574048B (en) | 2018-05-24 | 2021-06-16 | Oxford Nanopore Tech Ltd | Nanopore sensor component with electrostatic discharge protection |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| JP7492200B2 (ja) | 2019-03-12 | 2024-05-29 | オックスフォード ナノポール テクノロジーズ ピーエルシー | ナノ細孔センシングデバイスと操作方法およびその成形方法 |
| EP3977137B1 (en) | 2019-05-29 | 2026-04-01 | Nanjing University | Detection of analytes by nanopore without using electrodes |
| EP4034148A4 (en) | 2019-09-23 | 2025-09-10 | Harvard College | BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE |
| CN112831395B (zh) * | 2019-11-25 | 2024-01-16 | 深圳华大生命科学研究院 | 用于纳米孔测序的类细胞膜 |
| GB202004944D0 (en) | 2020-04-03 | 2020-05-20 | King S College London | Method |
| EP4675256A3 (en) | 2020-07-17 | 2026-01-28 | Oxford Nanopore Technologies PLC | Nanopore sensing device |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH067737A (ja) * | 1992-06-30 | 1994-01-18 | Junjiro Aoki | 累積膜の連続製造方法 |
| JP4248246B2 (ja) * | 2001-03-14 | 2009-04-02 | ジーイー・ヘルスケア・バイオ−サイエンシーズ・アーベー | 支持されたリピドフィルム膜の製造方法およびそれらの使用 |
| JP4394916B2 (ja) * | 2003-09-19 | 2010-01-06 | 独立行政法人科学技術振興機構 | 人工脂質二重膜の形成装置および人工脂質二重膜の形成方法、並びにその利用 |
| JP4394917B2 (ja) * | 2003-09-19 | 2010-01-06 | 独立行政法人科学技術振興機構 | 人工脂質二重膜を有する電流測定装置 |
| JP2005114576A (ja) * | 2003-10-08 | 2005-04-28 | Hitachi Software Eng Co Ltd | 両親媒性分子固定化ビーズ、その製造方法、及びキャピラリビーズアレイのビーズ配列方法 |
| GB0505971D0 (en) | 2005-03-23 | 2005-04-27 | Isis Innovation | Delivery of molecules to a lipid bilayer |
| WO2006110350A2 (en) | 2005-03-29 | 2006-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Method of fabricating lipid bilayer membranes on solid supports |
| US7857978B2 (en) | 2005-05-20 | 2010-12-28 | Aquaporin A/S | Membrane for filtering of water |
| JP5114702B2 (ja) * | 2005-07-29 | 2013-01-09 | 国立大学法人 東京大学 | 両親媒性単分子膜の接触による二分子膜の形成方法およびその装置 |
| EP1931981A1 (en) | 2005-09-07 | 2008-06-18 | Agresearch Limited | A method of manufacture |
| GB0614835D0 (en) * | 2006-07-26 | 2006-09-06 | Isis Innovation | Formation of bilayers of amphipathic molecules |
-
2007
- 2007-08-21 GB GBGB0716264.7A patent/GB0716264D0/en not_active Ceased
-
2008
- 2008-08-19 JP JP2010521469A patent/JP5797405B2/ja active Active
- 2008-08-19 CA CA2697024A patent/CA2697024C/en active Active
- 2008-08-19 US US12/733,275 patent/US20110041978A1/en not_active Abandoned
- 2008-08-19 EP EP08788371.6A patent/EP2183594B1/en active Active
- 2008-08-19 WO PCT/GB2008/002805 patent/WO2009024775A1/en not_active Ceased
- 2008-08-19 CN CN200880111401.7A patent/CN101821626B/zh active Active
-
2012
- 2012-10-16 US US13/652,481 patent/US8784929B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101821626B (zh) | 2015-04-08 |
| WO2009024775A1 (en) | 2009-02-26 |
| CA2697024A1 (en) | 2009-02-26 |
| WO2009024775A8 (en) | 2009-12-03 |
| CN101821626A (zh) | 2010-09-01 |
| US20130129910A1 (en) | 2013-05-23 |
| GB0716264D0 (en) | 2007-09-26 |
| EP2183594B1 (en) | 2018-11-07 |
| EP2183594A1 (en) | 2010-05-12 |
| US20110041978A1 (en) | 2011-02-24 |
| US8784929B2 (en) | 2014-07-22 |
| JP5797405B2 (ja) | 2015-10-21 |
| JP2010536551A (ja) | 2010-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2183594B1 (en) | Bilayers | |
| CN102687021B (zh) | 双层 | |
| Heron et al. | Direct detection of membrane channels from gels using water-in-oil droplet bilayers | |
| US7387715B2 (en) | Sample positioning and analysis system | |
| US7201836B2 (en) | Multiaperture sample positioning and analysis system | |
| Bayley et al. | Droplet interface bilayers | |
| US20090153153A1 (en) | Multiaperture sample positioning and analysis system | |
| US7408359B2 (en) | Current measuring device having artificial lipid bilayer membrane | |
| EP1677102A1 (en) | Artificial lipid double-membrane forming device and artificial lipid double-membrane forming method, and method of utilizing the same | |
| Weatherill et al. | Combining single-molecule imaging and single-channel electrophysiology | |
| CN1902497A (zh) | 分析芯片以及所述分析芯片用于测定分子结构和功能的用途 | |
| Suzuki et al. | Microtechnologies for membrane protein studies | |
| WO2002024862A2 (en) | Sample positioning and analysis system | |
| EP3164712B1 (en) | Microfluidic array supporting a lipid bilayer assembly | |
| Danelon et al. | Probing the function of ionotropic and G protein-coupled receptors in surface-confined membranes | |
| Craighead | Future lab-on-a-chip technologies for interrogating individual molecules | |
| JP2007503207A (ja) | ギャップ結合を含有する生化学活性検出用装置 | |
| US20240226882A1 (en) | Plasma Membrane on a Chip | |
| Stimberg | Microfluidic platform for bilayer experimentation–From a research | |
| Upadhye | Developing instrumentation for multi-parametric investigation of mechanisms of mechanosensitivity in ion channels | |
| Pace | Supported lipid bilayer electrophoresis: A new paradigm in membrane biophysics and separations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130731 |